Aureus Licenses AurSCOPE ADME/DDI and hERG Knowledge Databases to Siena
News Jun 08, 2006
Better understanding of the ADME-Tox properties of potential drug candidates is an integral part of the pharmaceutical industry’s current strategy to reduce the attrition rate in bringing new drugs to the market.
Aureus’ ADME/DDI and hERG knowledge databases contain detailed data including metabolism, inhibition, drug-drug interactions and pharmacokinetics which can help assess the safety of a potential pharmaceutical candidate.
"Aureus Pharma’s knowledge databases on ADME and hERG provide Siena Biotech researchers access to important data to assess ADME properties early in the drug discovery process and complement our in-house knowledge-based drug design platform," commented Siena Biotech’s Dr. Graeme M. Robertson, Vice President Therapeutic Research.
"We are very pleased that Siena Biotech has chosen Aureus Pharma's solutions," said Dr. Andre Michel, CEO of Aureus Pharma.
"Having access to the data in our ADME & hERG knowledge databases allows scientists to save valuable research time by using this prior knowledge and improve prioritization in drug discovery process."
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Chili Pepper Derived Anti-Obesity Drug Shows Promise in Animal TrialsNews
A novel drug based on capsaicin, the compound that gives chili peppers their spicy burn, caused long term weight loss and improved metabolic health in mice eating a high fat diet.READ MORE
5th edition of the International Conference Clinical Oncology and Molecular Diagnostics
Jun 17 - Jun 18, 2019